The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
Launched by KHYBER MEDICAL UNIVERSITY PESHAWAR · Dec 17, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether adding a medication called Ribavirin to the standard treatment for dengue fever can help prevent serious bleeding in patients. Dengue fever can sometimes lead to more severe forms of the illness, which can include dangerous bleeding. The trial is designed to find out if Ribavirin makes a difference in keeping patients safer from these bleeding events.
To participate in this trial, you need to be at least 18 years old and currently hospitalized with a confirmed dengue fever diagnosis. Certain patients may not be eligible, including those who are pregnant, have specific bleeding disorders, or are taking certain medications that affect blood clotting. If you join the trial, you will receive either the standard treatment or the standard treatment plus Ribavirin, and the study will closely monitor your health to see how well the treatments work. This research is important because it could lead to better care for patients with dengue fever.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female patients aged 18 years and above.
- * Hospitalized patients diagnosed with dengue fever, confirmed via:
- • Positive Dengue NS1 antigen test
- • Dengue IgM antibodies
- • Dengue RNA PCR.
- • Patients presenting with various severities of illness, as classified by the WHO dengue severity classification.
- Exclusion Criteria:
- • Patients taking antiplatelet or anticoagulant medications.
- • Patients with known bleeding disorders (e.g., hemophilia, von Willebrand disease, end-stage renal disease, or liver cirrhosis).
- • Patients with HIV undergoing antiviral therapy.
- • Pregnant women.
- • Patients with hypersensitivity to Ribavirin.
- • Patients with WHO Grade 1 bleeding (few petechiae without clinical significance).
About Khyber Medical University Peshawar
Khyber Medical University Peshawar is a leading academic institution dedicated to advancing medical education, research, and healthcare in Pakistan. With a commitment to excellence, the university plays a pivotal role in fostering clinical research initiatives that aim to improve patient outcomes and public health. Through its robust infrastructure and collaboration with local and international partners, Khyber Medical University Peshawar conducts innovative clinical trials that adhere to rigorous ethical standards and regulatory guidelines, contributing to the global body of medical knowledge and the development of effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Peshawar, Khyber Pakhtunkhwa, Pakistan
Peshawar, Khyber Pakhtunkhwa, Pakistan
Swābi, Khyber Pakhtunkhwa, Pakistan
Kohat, Kpk, Pakistan
Patients applied
Trial Officials
Said Amin, MBBS,FCPS
Principal Investigator
Department of Medicine Hayatabad Medical Complex Peshawar
Sheraz Fazid, MBBS,MPH
Principal Investigator
Institute of Public Health and Social Science, Khyber Medical University Peshawar
Noman Arif, MBBS
Principal Investigator
Institute of Public Health and Social Science, Khyber Medical University Peshawar
Akhtar Sherin, MBBS,MHR,PHD
Principal Investigator
Kohat Institute of Medical Science Peshawar Pakistan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported